All terms in NCIT
| Label | Id | Description |
|---|---|---|
| Grade 5 Other Infection, CTCAE | NCIT_C60017 | |
| Grade 5 Pancreas Infection Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils, CTCAE | NCIT_C60018 | |
| Grade 5 Pancreas Infection with Normal Absolute Neutrophil Count or Grade 1 or 2 Neutrophils, CTCAE | NCIT_C60019 | |
| Phase IIIa Trial | NCIT_C49687 | [A classification typically assigned retrospectively to a Phase III trial after regulatory authorities determined the need for a Phase III B trial.] |
| Phase III Trial | NCIT_C15602 | [A clinical research protocol designed to investigate the efficacy of the biomedical or behavioral intervention in large groups of human subjects (from several hundred to several thousand), to confirm efficacy, to monitor adverse reactions to the new medication or treatment regimen with respect to long-term use and by comparing the intervention to other standard or experimental interventions as well as to a placebo.] |
| Reactive Lymphocyte to Lymphocyte Ratio Measurement | NCIT_C74654 | [The determination of the ratio of reactive lymphocytes compared to all lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.] |
| Phase IIb Trial | NCIT_C49688 | [A clinical research protocol generally referred to as a well-controlled and pivotal trial that aims to prove the mechanism of action of the new intervention in question. A pivotal study will generally be well-controlled, randomized, of adequate size, and whenever possible, double-blind.] |
| Phase II Trial | NCIT_C15601 | [A clinical research protocol designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention.] |
| Sezary Cell to Lymphocyte Ratio Measurement | NCIT_C74655 | [The determination of the ratio of Sezary cells compared to all lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.] |
| Phase IIIb Trial | NCIT_C49689 | [A type of Phase III trial executed near the time of approval to elicit additional findings. This type of trial may be required as a condition of regulatory authority approval.] |
| Sickle Cell to Erythrocyte Ratio Measurement | NCIT_C74656 | [The determination of the ratio of sickle cells compared to all erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.] |
| Auer Rod Measurement | NCIT_C74657 | [The determination of the number of Auer rods present in a sample.] |
| Children 2-11 Years Old | NCIT_C49683 | [A person from 2 years to 11 years of age.] |
| Child | NCIT_C16423 | [A person who is not yet an adult. The specific cut-off age will vary by purpose.] |
| Precursor Plasma Cell to Lymphocyte Ratio Measurement | NCIT_C74650 | [The determination of the ratio of precursor plasma cells compared to all lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.] |
| Protein Furry Homolog-Like | NCIT_C126625 | [Protein furry homolog-like (3013 aa, ~340 kDa) is encoded by the human FRYL gene. This protein is involved in the regulation of cell shape in polarized cells.] |
| FRYL Gene | NCIT_C126623 | [This gene is involved in the regulation of cell shape and polarity.] |
| Prolymphocyte to Lymphocyte Ratio Measurement | NCIT_C74651 | [The determination of the ratio of prolymphocytes compared to all lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.] |
| EEFSEC Gene | NCIT_C126626 | [This gene plays a role in protein translation.] |
| GTP Binding | NCIT_C20979 | [GTP Binding is a molecular interaction between specific proteins (containing a GTP binding site) and guanosine 5-prime triphosphate during diverse cellular processes, such as RNA synthesis, translation, signal transduction, and cytoskeletal assembly.] |